> Details

Zimmerman, Kanecia O.; Wu, Huali; Maharaj, Anil; Turner, Alex; Chen, Jia-Yuh; Hornik, Chi D.; Arnold, Susan; Muller, William; Al-Uzri, Amira; Meyer, Marisa; Shiloh-Malawsky, Yael; Taravath, Sasidharan; Lakhotia, Arpita; Joshi, Charuta; Jackman, Jennifer; Hornik, Christoph P.

Pharmacokinetics and Proposed Dosing of Levetiracetam in Children With Obesity

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Pharmacokinetics and Proposed Dosing of Levetiracetam in Children With Obesity
  • Contributor: Zimmerman, Kanecia O.; Wu, Huali; Maharaj, Anil; Turner, Alex; Chen, Jia-Yuh; Hornik, Chi D.; Arnold, Susan; Muller, William; Al-Uzri, Amira; Meyer, Marisa; Shiloh-Malawsky, Yael; Taravath, Sasidharan; Lakhotia, Arpita; Joshi, Charuta; Jackman, Jennifer; Hornik, Christoph P.
  • Published: Pediatric Pharmacy Advocacy Group, 2023
  • Published in: The Journal of Pediatric Pharmacology and Therapeutics, 28 (2023) 8, Seite 693-703
  • Language: English
  • DOI: 10.5863/1551-6776-28.8.693
  • ISSN: 2331-348X; 1551-6776
  • Origination:
  • Footnote:
  • Description: OBJECTIVE Characterize levetiracetam pharmacokinetics (PK) in children with obesity to inform dosing. METHODS Children 2 to <21 years old receiving standard of care oral levetiracetam across two opportunistic studies provided blood samples. Levetiracetam plasma PK data were analyzed with a nonlinear mixed-effects modeling approach. Indirect measures for body size and covariates were tested for model inclusion. Individual empirical Bayesian estimates using the final model parameters were compared by obesity status. Monte Carlo simulation using total body weight was performed in children with normal estimated glomerular filtration rate to identify dosing for children with obesity that resulted in comparable exposures to normal weight adults and children after receiving label dosing. RESULTS The population PK model was developed from 341 plasma concentrations from 169 children. A 1-compartment model best fit the data with fat-free mass as a significant covariate. Compared with children with normal weight, children with obesity had significantly lower body weight-normalized clearance (median [range], 4.77 [1.49–10.44] and 3.71 [0.86–13.55] L/h/70 kg, respectively). After label dosing with the oral formulation in children with obesity 4 to <16 years old, maximum and minimum steady-state concentrations were higher (25% and 41%, respectively [oral solution] and 27% and 19%, respectively [tablet]) compared with children with normal weight. Comparable exposures between children with and without obesity were achieved with weight-tiered dosing regimens of <75 kg or ≥75 kg. CONCLUSIONS Weight-tiered dosing for levetiracetam oral solution and tablets for children with obesity 4 to <16 years old results in more comparable exposures to children of normal weight.
  • Access State: Open Access